BridgeMD
New treatment option for Severe Malaria
Official title PDMC Implementation Trial in Kenya
ClinicalTrials.gov ID: NCT06624631
What this study is testing
- What it's testing
- The goal of this implementation trial is to evaluate at least two alternative delivery strategies and adherence support for malaria chemoprevention with dihydroartemisinin-piperaquine in the post-discharge management of children hospitalised with severe anaemia or severe malaria to optimise adherence in Kenya. The actual interventions to be evaluated have been co-designed with national stakeholders during an initial formative research stage.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages up to 9
You may be able to join if
- CLUSTERS
- Health facilities with blood transfusion services offering in-patient care for children with severe anaemia and severe malaria.
- \>=40 children per year admitted with severe anaemia or severe malaria
- Agreement to participate by facility management
- Located in areas with moderate to high malaria transmission INDIVIDUAL PARTICIPANTS
You likely can't join if
- CLUSTERS \- Health facilities without subservient lower-level health facilities INDIVIDUAL PARTICIPANTS
- Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia)
- Sickle cell anaemia/sickle cell disease
- Body weight \<5 kg
- HIV infection and cotrimoxazole prophylaxis are not exclusion criteria.
See the full eligibility criteria
- CLUSTERS
- Health facilities with blood transfusion services offering in-patient care for children with severe anaemia and severe malaria.
- \>=40 children per year admitted with severe anaemia or severe malaria
- Agreement to participate by facility management
- Located in areas with moderate to high malaria transmission INDIVIDUAL PARTICIPANTS
- Aged \<10 years of both sexes
- Hospitalised with severe anaemia or severe malaria: Initially hospitalised with haemoglobin \<5.0 g/dl or PCV \<15%, or requirement for blood transfusion for other clinical reasons on or during admission to the...
- CLUSTERS \- Health facilities without subservient lower-level health facilities INDIVIDUAL PARTICIPANTS
- Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia)
- Sickle cell anaemia/sickle cell disease
- Body weight \<5 kg
- HIV infection and cotrimoxazole prophylaxis are not exclusion criteria.
The study team makes the final eligibility decision.
Where it's taking place
- Kisumu, Kenya
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, up to 9 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kisumu, Kenya. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.